Date published: 2026-5-16

1-800-457-3801

SCBT Portrait Logo
Seach Input

1700019M22Rik Inhibitors

Chemical inhibitors of the protein 1700019M22Rik function by obstructing specific signaling pathways and enzymatic activities that lead to its activation. Staurosporine operates as a broad-spectrum protein kinase inhibitor, which means it can inhibit the activity of various kinases that would normally phosphorylate and activate 1700019M22Rik. Similarly, wortmannin and LY294002 are both inhibitors of PI3K, a kinase that participates in a wide array of cellular functions, including the activation of downstream proteins such as 1700019M22Rik. If 1700019M22Rik is indeed a downstream target of PI3K, these inhibitors would prevent its activation by halting the upstream signaling.

Rapamycin specifically inhibits mTOR, a key component of the mTOR signaling pathway, which is crucial for protein synthesis and cell growth. If 1700019M22Rik is involved in this pathway, rapamycin would suppress its activity by preventing the pathway's progression. Triciribine targets AKT, another kinase involved in critical survival and proliferation pathways. The inhibition of AKT by triciribine can lead to a decrease in the activity of 1700019M22Rik, assuming 1700019M22Rik is a downstream effector in the AKT pathway. SP600125 and lestaurtinib are inhibitors of JNK and JAK2, respectively. SP600125 would decrease the activity of 1700019M22Rik by inhibiting JNK, which could be a kinase that activates 1700019M22Rik. Lestaurtinib would lead to reduced activity of 1700019M22Rik by inhibiting JAK2, which may regulate 1700019M22Rik through the JAK-STAT signaling pathway. SB203580, PD98059, and U0126 are inhibitors of different kinases within the MAPK pathway, namely p38 MAPK and MEK. By inhibiting these kinases, they would prevent the activation of the ERK pathway and, consequently, the activity of 1700019M22Rik if it lies downstream. Lastly, PP2 and dasatinib are inhibitors of Src family kinases and BCR-ABL, respectively. By inhibiting these kinases, these chemicals would suppress the activation of downstream proteins, which includes 1700019M22Rik, provided it is regulated by these kinases.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$153.00
$396.00
113
(4)

Staurosporine inhibits a broad range of protein kinases, which could include those that phosphorylate 1700019M22Rik, thereby preventing its activation.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

Wortmannin is a PI3K inhibitor. Since PI3K signaling can lead to activation of downstream proteins, inhibiting PI3K can reduce the activation of 1700019M22Rik assuming it is downstream of PI3K.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY294002, another PI3K inhibitor, functions similarly to Wortmannin. It would inhibit the PI3K pathway and therefore decrease the activity of 1700019M22Rik when it is a downstream effector.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

Rapamycin inhibits mTOR, which is part of the mTOR signaling pathway. Inhibition of this pathway will decrease activity of downstream proteins, including 1700019M22Rik, when it is associated with this pathway.

Triciribine

35943-35-2sc-200661
sc-200661A
1 mg
5 mg
$104.00
$141.00
14
(1)

Triciribine specifically inhibits AKT, which is involved in survival and proliferation signaling pathways. By inhibiting AKT, triciribine could decrease the activity of 1700019M22Rik if it is a downstream target of AKT signaling.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 is an inhibitor of JNK, and by inhibiting JNK, it could reduce the activity of 1700019M22Rik, assuming that JNK phosphorylates or otherwise activates 1700019M22Rik.

Lestaurtinib

111358-88-4sc-218657
sc-218657A
sc-218657B
1 mg
5 mg
10 mg
$275.00
$326.00
$612.00
3
(1)

Lestaurtinib inhibits JAK2, and if 1700019M22Rik is activated by JAK2 or is part of the JAK-STAT signaling pathway, inhibition by lestaurtinib would decrease its activity.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

SB203580 is an inhibitor of p38 MAPK. Inhibition of p38 MAPK would lead to decreased activity of 1700019M22Rik if it is involved in p38 MAPK signaling.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

PD98059 inhibits MEK, which is upstream of ERK in the MAPK pathway. By inhibiting MEK, PD98059 would reduce the activation of downstream proteins, possibly including 1700019M22Rik as part of this pathway.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$64.00
$246.00
136
(2)

U0126 is another MEK inhibitor, operating similarly to PD98059. It would prevent the activation of ERK and potentially reduce the activity of 1700019M22Rik if it is implicated in the MEK/ERK pathway.